Evidence map›Paper›PMID 39742369›Full record

ArticleThe breast journal2024

The Impact of the Coexpression of

Nehad M Ayoub, Ghaith M Al-Taani, Amer E Alkhalifa, Dalia R Ibrahim, Aymen Shatnawi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The breast journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nehad M AyoubDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. BOX: 3030, Irbid 22110, Jordan.ORCID 0000-0003-2284-4370
Ghaith M Al-TaaniDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.ORCID 0000-0001-7745-4885
Amer E AlkhalifaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. BOX: 3030, Irbid 22110, Jordan.ORCID 0000-0002-6872-4780
Dalia R IbrahimDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. BOX: 3030, Irbid 22110, Jordan.
Aymen ShatnawiDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, 70 President St., Charleston, SC 29425, USA.ORCID 0000-0001-6435-3727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Breast cancer is a heterogeneous disease. Exploring new prognostic and therapeutic targets in patients with breast cancer is essential. This study investigated the expression of MET, ESR1, and ESR2 genes and their association with clinicopathologic characteristics and clinical outcomes in patients with breast cancer. Methods: The METABRIC dataset for breast cancer was obtained from the cBioPortal public domain. Gene expression data for Results: The Conclusions: Findings from our study add to the growing evidence on the potential crosstalk between MET and estrogen receptors in breast cancer. The expression of the MET/ESR genes could be a novel prognosticator and calls for future studies to evaluate the impact of combinational treatment approaches with MET inhibitors and endocrine drugs in breast cancer.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaProto-Oncogene Proteins c-metAdultAgedBiomarkers, TumorDNA Copy Number VariationsEstrogen Receptor betaFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisReceptors, EstrogenBiomarkers, TumorESR1 protein, humanESR2 protein, humanEstrogen Receptor alphaEstrogen Receptor betaMET protein, humanProto-Oncogene Proteins c-metReceptors, Estrogen

Identifiers

PMID39742369
PMCPMC11098610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.